Skip to content

Melanoma epidemiology and global burden

TL;DR — Cutaneous melanoma is a low-incidence, high-variance cancer: an estimated 325,000 new cases and 57,000 deaths worldwide in 2020, with age-standardised incidence ranging from 42 per 100,000 person-years in Australian and New Zealand men to commonly under 1 per 100,000 across Africa and Asia, and projected to reach 510,000 cases and 96,000 deaths by 2040 on unchanged rates (Arnold 2022, PMID 35353115). Incidence and mortality have decoupled: incidence rose several-fold in light-skinned populations while age-standardised mortality has fallen in most high-income countries, sharply so in the US after 2013 (annual percent change −6.2%, 95% CI −8.7 to −3.7, 2013–2016) coincident with the arrival of checkpoint and targeted therapy (Berk-Krauss 2020, PMID 32191523). Birth-cohort analyses in Australia, Sweden, the US, Canada and Italy now consistently show falling age-specific incidence in cohorts born from roughly the mid-1960s onward, the first population-scale evidence that primary prevention changed the disease (Aitken 2018, PMID 29105744; Helgadottir 2024, PMID 39245436; Thrift 2020, PMID 31346623; O'Sullivan 2026, PMID 41932245). The central interpretive hazard is that a large and disputed share of the incidence series is overdiagnosis, so incidence and burden numbers are not interchangeable with disease occurrence — see screening and overdiagnosis.

Global counts and rates

Measure Estimate Year Source
New cases worldwide 325,000 (174,000 M / 151,000 F) 2020 Arnold 2022, PMID 35353115
Deaths worldwide 57,000 (32,000 M / 25,000 F) 2020 PMID 35353115
New cases worldwide 331,722 2022 (GLOBOCAN) Wang 2025, PMID 39682020
Deaths worldwide 58,667 2022 (GLOBOCAN) PMID 39682020
New cases worldwide ~330,000 2022 Oh 2026, PMID 42502459
Projected cases 510,000 (≈+50%) 2040 PMID 35353115
Projected deaths 96,000 (+68%) 2040 PMID 35353115
Age-standardised incidence 3.4 per 100,000 2020 Huang 2023, PMID 37296344
Age-standardised mortality 0.55 per 100,000 2020 PMID 37296344
Rank among cancers worldwide 17th most common 2022 PMID 39682020
Share of cases attributable to UV radiation ~88% (5th-percentile reference) 2022 PMID 42502459

Melanoma is a small fraction of skin cancer by count and most of it by mortality: melanoma represents about 1% of skin cancers but causes the most skin-cancer deaths in the US framing used by the USPSTF (Mangione 2023, PMID 37071089), and in the European guideline framing accounts for 90% of skin-cancer mortality (Garbe 2025, PMID 39700658). Non-melanoma skin cancer nonetheless now causes more absolute deaths worldwide than melanoma (69,416 vs 58,667 in 2022) because of its enormous case count (PMID 39682020). Global cancer statistics for 2024 place total cancer incidence at 20.6 million cases with a projected 67% rise to 34.4 million by 2050, largest proportionally in lower-HDI countries — the demographic engine behind melanoma's own projections (Sung 2026, PMID 42417444).

The forty-fold geographic gradient

Region Male ASR per 100,000 Female ASR per 100,000
Australia / New Zealand 42 31
Western Europe 19 19
North America 18 14
Northern Europe 17 18
Most of Africa and Asia commonly <1 commonly <1

Source: GLOBOCAN 2020 (Arnold 2022, PMID 35353115). Mortality rates peaked at 5 per 100,000 person-years in New Zealand and vary far less than incidence (PMID 35353115) — the ratio of incidence variation to mortality variation is itself the core epidemiological fact of this disease. Queensland holds the highest recorded rate anywhere: age-standardised invasive melanoma incidence 72 per 100,000 per year in 2010–2014 (Aitken 2018, PMID 29105744). HDI is positively associated with incidence for both melanoma and non-melanoma skin cancer, and positively with melanoma mortality, while mortality-to-incidence ratios are highest in low-HDI settings (PMID 39682020; PMID 42502459).

Trend structure: incidence up, mortality down, cohorts turning

Incidence. US non-Hispanic White incidence rose from 20.7 (95% CI 20.5–20.9) per 100,000 in 2001 to 28.2 (28.0–28.5) in 2015, with annual increases of 3.90% (2.36–5.48) 2001–2005 and 1.68% (1.37–1.99) 2005–2015 (Thrift 2020, PMID 31346623). Across 18 European registries covering 117 million people and ~415,000 lesions, 1995–2012, invasive incidence rose 4.0%/year in men and 3.0% in women, in situ 7.7% and 6.2%, and thin invasive 10% and 8.3% (Sacchetto 2018, PMID 29395684). In Italy, age-standardised incidence rose 3.6%/year (3.2–4.0) in men and 2.5% (2.0–3.1) in women 1994–2013 (Bucchi 2021, PMID 33405292).

Mortality. US age-adjusted melanoma mortality fell from 2.7 to 2.0 per 100,000 between 1999 and 2020 (−1.3%/year), with 184,416 melanoma deaths recorded, and the steepest decline in non-Hispanic White people after 2013 at −6.1%/year (Didier 2024, PMID 38956559). The inflection is sharp and dated: overall US White mortality rose 7.5% from 1986 to 2013, then fell 17.9% from 2013 to 2016 (APC −6.2%, −8.7 to −3.7), with men aged ≥50 falling at −8.3%/year (−12.2 to −4.1) from 2014 — a decline the authors call the largest and most sustained ever observed in melanoma (Berk-Krauss 2020, PMID 32191523). Ten new FDA approvals for metastatic melanoma from 2011 onward are the proposed cause. Globally, mortality trends have been favourable in most high-income countries, with Australian mortality down 40–50% over recent decades (De Pinto 2024, PMID 38391175).

Cohort turning points. The most informative signal is not the period trend but the birth-cohort trend.

Population Cohort finding Source
Queensland, Australia, 1995–2014 Age-specific invasive incidence under 40 falling from cohorts born ~mid-1960s, steepest for those born ~1980 and later Aitken 2018, PMID 29105744
New South Wales, 1988–2014 Invasive incidence stable or falling under 60, rising ≥60 especially in men; in situ rising in all age groups Blazek 2022, PMID 36174452
US non-Hispanic White, 2001–2015 Age-specific relative risk rose for cohorts ~1921–1981 then fell; 1991 cohort IRR 0.85 (0.77–0.94) vs 1956 cohort Thrift 2020, PMID 31346623
Sweden, 1990–2022, 34,800 melanomas in under-60s Incidence peaked 2013–2015 in ages 20–49 then stable or declining; mortality fell significantly in ages 30–59 but not ≥60 Helgadottir 2024, PMID 39245436
Canada, 1992–2022 Incidence falling in females <30 and males <40; cohorts born 1993–2007 have lower incidence than the baby-boom reference O'Sullivan 2026, PMID 41932245
Italy, 1994–2013, 21 registries / 15.8 M people Cohort IRR rose to the 1973 (women) / 1975 (men) cohorts then declined toward the 1949 reference Bucchi 2021, PMID 33405292
Iceland, 1957–2021 Invasive world-standardised rate peaked 2002–2006 then fell; melanoma mortality falling since 2012 Thomas 2025, PMID 39444324

The Australian and Icelandic reversals are the two cases with a specific attributed exposure — sun-protection campaigns from the early 1980s in Queensland (PMID 29105744; PMID 36174452) and sunbed regulation plus campaigning in Iceland (PMID 39444324; de Gruijl 2022, PMID 36191966). Neither study establishes causation, and the Swedish authors state explicitly that they evaluated none of the candidate explanations (PMID 39245436).

Survival

Endpoint Value Era Source
US 5-year relative survival, metastatic melanoma 16% → 35% mid-1990s → 2015–2021 Siegel 2026, PMID 41528114
US 1-year net survival, distant stage ~43% stable 2001–2010 → 58.9% (56.6–61.2) in 2013 CONCORD-3 Di Carlo 2020, PMID 33409455
Share of US melanomas diagnosed distant stage 4.4% of 425,915 2001–2013 PMID 33409455
Melanoma-specific mortality, Olmsted County cohort 26.7% (1970s) → 1.5% (2010s) 50-year cohort, n = 2,310 Reinhart 2024, PMID 38957842

The distant-stage survival improvement begins in 2010, before most approvals took effect at population scale, and continues afterward; CONCORD-3 attributes it to checkpoint inhibitors and targeted agents while noting persistently lower survival in Black than White patients at every year examined (PMID 33409455). Whether population mortality decline is attributable to therapy, to earlier detection, or to a changing case mix of low-lethality lesions cannot be resolved from registry data alone (PMID 38956559; PMID 32191523).

Burden metrics beyond counts

US Global Burden of Disease estimates for 2019 give melanoma age-standardised incidence 17.0, prevalence 138, DALYs 64.8 and mortality 2.2 per 100,000 — against squamous cell carcinoma at 262 incidence but 26.6 DALYs, and basal cell carcinoma at 525 incidence and 0.2 DALYs (Aggarwal 2021, PMID 33852922). The DALY-to-incidence ratio is the cleanest single expression of why melanoma dominates skin-cancer burden despite being uncommon. In the ≥60 population globally, GBD 2021 shows incidence rising (EAPC 0.65, 95% CI 0.33–0.96) and prevalence rising (1.02, 0.64–1.41) while mortality (−0.43, −0.57 to −0.30) and DALYs (−0.67, −0.82 to −0.53) fall (Du 2025, PMID 41425115).

Sex, site and age structure

Melanoma is more frequent in males in most world regions (PMID 35353115), but the sex difference is site-structured and generation-dependent. Analysis of Queensland, US White and Scottish data 1982–2018 found melanoma incidence always highest on the trunk in men, historically highest on limbs in women with recent rises in truncal melanoma among women in all three populations, a female excess on the lower limb across most age groups, and a male excess on trunk from about age 25 and head/neck from about age 40 that widens with age (Olsen 2025, PMID 38897542). The authors read this as etiologic heterogeneity between the sexes rather than a single UV dose–response. Incidence rises steeply with age everywhere; the Swedish, Canadian and Australian cohort analyses all show the burden shifting into older ages as younger cohorts improve (PMID 39245436; PMID 41932245; PMID 36174452).

Disparities

  • Incidence is ~30-fold higher in White than Black people in the US, but stage at diagnosis is worse in people with darker skin (PMID 37071089). Melanoma in skin of colour is diagnosed at more advanced stages with worse survival, and the subtype mix differs — acral lentiginous and mucosal melanoma account for a larger share of diagnoses (Brunsgaard 2023, PMID 35533771). See acral and mucosal melanoma.
  • Survival gaps persist within stage. In CONCORD-3, distant-stage 1-year net survival improved in both Black and White patients but remained consistently lower in Black patients, which the authors attribute to differential treatment access (PMID 33409455).
  • Rural populations in the US have higher melanoma mortality than urban and suburban populations (PMID 38956559).
  • Socioeconomic position and melanoma incidence are positively correlated, which is the observation the overdiagnosis literature reads as detection intensity and the counter-literature reads as real exposure differences (Adamson 2022, PMID 36190719; Clarke 2017, PMID 28736233; Lal 2025, PMID 40637374).
  • Mortality-to-incidence ratios are highest in low-HDI settings, and UVR-attributable case growth to 2050 is projected steepest there (PMID 42502459; PMID 39682020).

Subtype shares of the burden

Melanoma's headline statistics are cutaneous statistics; the non-cutaneous subtypes have their own, far smaller and far worse, series.

Subtype Incidence / count Survival Source
Cutaneous 219,890 SEER cases 1988–2010 5-year relative survival 89% Bishop 2014, PMID 24272143
Ocular (predominantly uveal) 7,069 SEER cases 1988–2010; mean age-adjusted incidence 5.6 per million (95% CI 5.5–5.7), 1975–2020 5-year relative survival 78% (1988–2010); 82.8% and unchanged 1975–2016 PMID 24272143; Weinberger 2025, PMID 40225965
Mucosal (all sites) 2,755 SEER cases 1988–2010; incidence rises exponentially with age, unlike cutaneous 5-year relative survival 34% aggregate, range 3–69% by site PMID 24272143
Acral 1,000 cases, Swedish national registry 1990–2020; no significant change in standardised incidence 1996–2020 despite rising absolute counts 5-year melanoma-specific survival 75.8–77.9% (F), 62.4–71.7% (M) Helkkula 2024, PMID 39140487

Two structural facts follow. First, ocular and mucosal melanoma showed no survival improvement across 1988–2010 while cutaneous melanoma did (PMID 24272143) — a divergence that predates the immunotherapy era and widened during it. Second, the stability of acral incidence against sharply rising cutaneous incidence is the strongest population-level evidence that the cutaneous rise is UV- or detection-driven rather than a general melanocytic phenomenon (PMID 39140487). Details in uveal melanoma and acral and mucosal melanoma.

Economic and life-years burden

Measure Estimate Population / era Source
Adults treated for any skin cancer, annual average 6.1 million (95% CI 5.6–6.6) US, 2016–2018 Kao 2023, PMID 36449145
Annual US skin-cancer treatment cost $8.0 bn (2012–15) → $8.9 bn (2016–18) US, MEPS PMID 36449145
Adults with melanoma, annual 0.70 million (0.61–0.78) US, MEPS 2011–2020 Olateju 2024, PMID 39612258
Total annual healthcare expenditure per person with melanoma $19,427 (vs $13,744 NMSC, $23,741 other cancers) same PMID 39612258
Adjusted marginal expenditure, melanoma vs other cancers −$3,369 (−$5,934 to −$804) same PMID 39612258
Years of life lost per patient, metastatic melanoma, Australia 19.9 (men) / 22.7 (women) 12-country model, 2014 Thiam 2016, PMID 26531249
Years of life lost per patient, metastatic melanoma, US 17.9 (men) / 20.6 (women) same PMID 26531249

Melanoma's economic signature is unusual: per-person expenditure is lower than for other non-skin cancers, but years of life lost per metastatic patient — 16–23 years across twelve countries — is among the highest of any solid tumour because the disease strikes younger than most (PMID 39612258; PMID 26531249). The cost estimates predate full population penetration of adjuvant checkpoint therapy and should be treated as a floor.

Interpretation rules for this page

  • Do not treat an incidence series as a disease-occurrence series. In US counties, incidence and melanoma mortality correlate at r = 0.09 (PMID 36190719).
  • Always state whether in situ lesions are included. In situ incidence rises faster than invasive incidence in every European registry examined (PMID 29395684).
  • Distinguish period from cohort effects. Period trends in most countries are still rising while cohort trends have already turned (PMID 31346623; PMID 41932245).
  • Age-standardised rate declines coexist with absolute count increases because populations are ageing and growing; the 2040 projection is generated by holding 2020 rates fixed (PMID 35353115).
  • GLOBOCAN, GBD and registry estimates are not interchangeable. GLOBOCAN 2020 gives 325,000 cases, GLOBOCAN 2022 gives 331,722, and GBD-derived analyses give different age-standardised rates for overlapping years; they are shown side by side here rather than averaged (PMID 35353115; PMID 39682020; PMID 33852922).

Open questions

  • What fraction of the projected rise to 510,000 cases by 2040 represents disease rather than detection (PMID 35353115; PMID 35293957)?
  • Are the cohort reversals in Australia, Iceland, Sweden, Canada and Italy attributable to sun-protection behaviour, and if so which components? No study has tested the attribution (PMID 29105744; PMID 39245436).
  • How much of the post-2013 mortality decline is therapy and how much is case-mix change? The decline is dated precisely but not decomposed (PMID 32191523; PMID 38956559).
  • Why do sex-specific site patterns differ and change across generations in the same direction in three populations with very different ambient UV (PMID 38897542)?
  • Will UVR-attributable burden growth in low- and medium-HDI settings materialise as projected, given that those registries have the weakest ascertainment (PMID 42502459)?

References

  1. Arnold M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA dermatology. 2022;158:495-503. PMID 35353115
  2. Berk-Krauss J, et al. New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016. American journal of public health. 2020;110:731-733. PMID 32191523
  3. Aitken JF, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. International journal of cancer. 2018;142:1528-1535. PMID 29105744
  4. Helgadottir H, et al. Melanoma Incidence and Mortality Trends Among Patients Aged 59 Years or Younger in Sweden. JAMA dermatology. 2024;160:1201-1210. PMID 39245436
  5. Thrift AP, et al. Melanoma Incidence Among Non-Hispanic Whites in All 50 US States From 2001 Through 2015. Journal of the National Cancer Institute. 2020;112:533-539. PMID 31346623
  6. O'Sullivan DE, et al. Age-specific melanoma incidence trends in Canada. Cancer epidemiology. 2026;102:103062. PMID 41932245
  7. Wang M, et al. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chinese medical journal. 2025;138:185-192. PMID 39682020
  8. Oh J, et al. Global patterns of melanoma, burden attributable to ultraviolet radiation exposure, and projections to 2050 across 185 countries: A population-based study with global modeling. JAAD international. 2026;27:149-159. PMID 42502459
  9. Huang J, et al. Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries. American journal of clinical dermatology. 2023;24:965-975. PMID 37296344
  10. Mangione CM, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329:1290-1295. PMID 37071089
  11. Garbe C, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. European journal of cancer (Oxford, England : 1990). 2025;215:115152. PMID 39700658
  12. Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: a cancer journal for clinicians. 2026;76:e70090. PMID 42417444
  13. Sacchetto L, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. European journal of cancer (Oxford, England : 1990). 2018;92:108-118. PMID 29395684
  14. Bucchi L, et al. Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy. International journal of cancer. 2021;148:835-844. PMID 33405292
  15. Didier AJ, et al. Patterns and trends in melanoma mortality in the United States, 1999-2020. BMC cancer. 2024;24:790. PMID 38956559
  16. De Pinto G, et al. Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma research. 2024;34:265-275. PMID 38391175
  17. Blazek K, et al. The impact of skin cancer prevention efforts in New South Wales, Australia: Generational trends in melanoma incidence and mortality. Cancer epidemiology. 2022;81:102263. PMID 36174452
  18. Thomas S, et al. Declining invasive and rising in situ melanoma incidence trends in Iceland: A nationwide cohort study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2025;39:1278-1284. PMID 39444324
  19. DE Gruijl FR, et al. Cutaneous Melanoma: Sheep in Wolves Clothing?. Anticancer research. 2022;42:5021-5025. PMID 36191966
  20. Siegel RL, et al. Cancer statistics, 2026. CA: a cancer journal for clinicians. 2026;76:e70043. PMID 41528114
  21. Di Carlo V, et al. Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). JNCI cancer spectrum. 2020;4:pkaa078. PMID 33409455
  22. Reinhart JP, et al. Incidence and mortality trends of primary cutaneous melanoma: A 50-year Rochester Epidemiologic Project study. JAAD international. 2024;16:144-154. PMID 38957842
  23. Aggarwal P, et al. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. Journal of the American Academy of Dermatology. 2021;85:388-395. PMID 33852922
  24. Du Z, et al. Global Burden and Trends of Cutaneous Malignant Melanoma in the Elderly Population: Analysis of Global Burden of Disease Study 2021. Clinical, cosmetic and investigational dermatology. 2025;18:3429-3442. PMID 41425115
  25. Olsen CM, et al. Does Sex Matter? Temporal Analyses of Melanoma Trends among Men and Women Suggest Etiologic Heterogeneity. The Journal of investigative dermatology. 2025;145:135-143. PMID 38897542
  26. Brunsgaard EK, et al. Melanoma in skin of color: Part I. Epidemiology and clinical presentation. Journal of the American Academy of Dermatology. 2023;89:445-456. PMID 35533771
  27. Adamson AS, et al. Association of UV Radiation Exposure, Diagnostic Scrutiny, and Melanoma Incidence in US Counties. JAMA internal medicine. 2022;182:1181-9. PMID 36190719
  28. Clarke CA, et al. Continued Increase in Melanoma Incidence across all Socioeconomic Status Groups in California, 1998-2012. The Journal of investigative dermatology. 2017;137:2282-2290. PMID 28736233
  29. Lal T, et al. Socioeconomic Influences on Melanoma Incidence Patterns by Stage in the US. Journal of surgical oncology. 2025;132:465-472. PMID 40637374
  30. Bishop KD, et al. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. International journal of cancer. 2014;134:2961-71. PMID 24272143
  31. Weinberger Y, et al. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1975-2020). Ocular oncology and pathology. 2025;11:30-36. PMID 40225965
  32. Helkkula T, et al. Acral Melanoma Incidence and Survival Trends in 1990-2020: A Nationwide, Population-based Study. Acta dermato-venereologica. 2024;104:adv40242. PMID 39140487
  33. Kao SZ, et al. Economic burden of skin cancer treatment in the USA: an analysis of the Medical Expenditure Panel Survey Data, 2012-2018. Cancer causes & control : CCC. 2023;34:205-212. PMID 36449145
  34. Olateju OA, et al. Marginal health care expenditures for melanoma care in the United States. Journal of managed care & specialty pharmacy. 2024;30:1364-1374. PMID 39612258
  35. Thiam A, et al. Years of life lost due to metastatic melanoma in 12 countries. Journal of medical economics. 2016;19:259-64. PMID 26531249
  36. Adamson AS, et al. Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. JAMA dermatology. 2022;158:426-431. PMID 35293957